mirvetuximab soravtansine (Elahere)

following a full submission assessed under the end of life and orphan equivalent medicine process:

mirvetuximab soravtansine (Elahere®) is accepted for use within NHSScotland.

Indication under review: as monotherapy for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens.

In an open-label, phase III study, treatment with mirvetuximab soravtansine was associated with significant improvements in progression free survival and overall survival compared with chemotherapy. An indirect treatment comparison versus bevacizumab plus chemotherapy did not identify any difference in efficacy, safety outcomes may favour mirvetuximab soravtansine.

This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.

This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.